For children with febrile urinary tract infection (UTI), stopping antibiotic treatment 3 days after clinical improvement increased the risk of recurrence but reduced antibiotic use and related side ...

US and MCUG for all children aged <2 years. 99m Tc–DMSA scan in high-grade reflux [3] Urinary tract infection (UTI) is the most common serious bacterial infection in childhood, and its ...

Between July 2006 and July 2008, we prospectively collected data on 209 children (median age of 10 months; 0.2–204 months) who were diagnosed with a clinically proven first episode of UTI at the ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Discover how individualised treatment for febrile UTIs lowers antibiotic use and reduces adverse events in children.

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

The UTI Children's Hybrid Fund- Direct has an AUM of 4316.01 crores & has delivered CAGR of 13.82% in the last 5 years. The fund has an exit load of 0.00% and an expense ratio of 1.54%.

In kids with a febrile urinary tract infection (UTI), an individualized duration of antibiotics led to an increased risk of recurrent UTI compared with a 10-day course. However, the individualized ...